Krebsmutationen Deep Dives: EGFR-Update nach dem ESMO-Kongress 2025!

After HER2, it's finally HER1's turn again, or in other words: EGFR! Today, an update on the "classic" activating mutations (exon 19del and L858R) – for the past few years, osimertinib reigned supreme as a monotherapy. Now, two combination studies are challenging that position. We also have news regarding the treatment line after osimertinib, as well as data on intensifying local procedures during systemic therapy. Enjoy! Osimertinib monotherapy has been the dominant treatment option for these mutations for years. Our latest update on EGFR mutations (just a year old):    • Krebsmutationen Deep Dives: EGFR-Update 2024!   Our video on EGFR as a therapeutic target:    • Krebsmutationen: EGFR - das Protein, das d...   Our video on exon 20 insertions in EGFR and HER2:    • Krebsmutationen Deep Dives: Exon 20-Insert...   00:00 Cancer Mutations Deep Dives: EGFR Update after the ESMO Congress 2025! 00:41 Welcome [SKIP INTRO] 01:05 REVIEW: FLAURA2 and MARIPOSA PFS 03:46 Between conferences... 05:23 FLAURA2 and MARIPOSA OS 09:31 Sacituzumab Tirumotecan 13:42 NorthStar study 17:42 CONCLUSION 18:30 OUTRO ______________________________ Music: "I Been All Alone" by Dev Do it [Epidemic Sound]